Wu Hsing-Ju, Chu Pei-Yi
Research Assistant Center, Show Chwan Memorial Hospital, Changhua 500, Taiwan.
Department of Medical Research, Chang Bing Show Chwan Memorial Hospital, Lukang Town, Changhua 505, Taiwan.
Cancers (Basel). 2022 Apr 19;14(9):2052. doi: 10.3390/cancers14092052.
Breast cancer is the most commonly diagnosed cancer and leading cause of cancer mortality among woman worldwide. The techniques of diagnosis, prognosis, and therapy monitoring of breast cancer are critical. Current diagnostic techniques are mammography and tissue biopsy; however, they have limitations. With the development of novel techniques, such as personalized medicine and genetic profiling, liquid biopsy is emerging as the less invasive tool for diagnosing and monitoring breast cancer. Liquid biopsy is performed by sampling biofluids and extracting tumor components, such as circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free mRNA (cfRNA) and microRNA (miRNA), proteins, and extracellular vehicles (EVs). In this review, we summarize and focus on the recent discoveries of tumor components and biomarkers applied in liquid biopsy and novel development of detection techniques, such as surface-enhanced Raman spectroscopy (SERS) and microfluidic devices.
乳腺癌是全球女性中最常被诊断出的癌症,也是癌症死亡的主要原因。乳腺癌的诊断、预后和治疗监测技术至关重要。当前的诊断技术是乳房X光检查和组织活检;然而,它们存在局限性。随着个性化医疗和基因分析等新技术的发展,液体活检正成为诊断和监测乳腺癌的侵入性较小的工具。液体活检通过采集生物流体样本并提取肿瘤成分来进行,这些成分包括循环肿瘤细胞(CTC)、循环肿瘤DNA(ctDNA)、游离mRNA(cfRNA)和微小RNA(miRNA)、蛋白质以及细胞外囊泡(EV)。在本综述中,我们总结并聚焦于液体活检中应用的肿瘤成分和生物标志物的最新发现以及检测技术的新进展,如表面增强拉曼光谱(SERS)和微流控装置。